Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TYRA-300-B01 · 1 trial · 1 indication
maximum plasma concentration (Cmax)
maximum steady-state plasma concentration (Cmax)
average steady-state trough plasma concentration (Cmin)
time to reach maximum plasma concentration (Tmax)
area under the plasma concentration-time curve (AUC)
apparent total clearance (CL/F)
apparent volume of distribution (Vz/F)
half-life of TYRA-300
accumulation ratio for Cmax (RCmax)
accumulation ratio for AUC
| Arm | Type | Description |
|---|---|---|
| Bioavailability Tablet vs Capsule Formulation | EXPERIMENTAL | TYRA-300-B01 single oral dose of tablet or capsule crossover followed by twice-daily tablet dosing |
| Food Effect Tablet Formulation | EXPERIMENTAL | TYRA-300-B01 single oral dose of tablet in the fed and fasted state |
| Pharmacokinetic Tablet Formulation | EXPERIMENTAL | TYRA-300-B01 single oral dose |
| Pharmacokinetic Mini-Tablet Formulation | EXPERIMENTAL | TYRA-300-B01 multiple-dose mini-tablet formulation |
| Name | Type | Description |
|---|---|---|
| TYRA-300-B01 | DRUG | TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3. |
Inclusion Criteria: * Males or females of non-childbearing potential, between 18 and 55 years of age * In good health, determined by no clinically significant findings from medical history, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory assessments * Body mass index (BMI) 18 ...
TYRA-300-B01 is an investigational small molecule developed by Tyra Biosciences, Inc. It is being studied in a Phase 1 clinical trial, and no approved indication has been disclosed. The compound is designed to target FGFR3.
TYRA-300-B01 targets FGFR3, a fibroblast growth factor receptor. By interacting with FGFR3, the small molecule is intended to modulate signaling pathways associated with this receptor. The specific therapeutic applications are not yet publicly disclosed.
TYRA-300-B01 is being developed by Tyra Biosciences, Inc., a biopharmaceutical company. The company's ticker symbol is TYRA. Tyra Biosciences is responsible for the research and clinical development of this investigational asset.
TYRA-300-B01 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any regulatory authority. The ongoing Phase 1 trial is evaluating the drug in healthy adult participants.
TYRA-300-B01 is being evaluated in a Phase 1 trial, NCT06006702, titled A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants. The trial is active but not recruiting, with an estimated enrollment of 60 participants in Australia.